163 related articles for article (PubMed ID: 32708856)
1. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women.
Gentry-Maharaj A; Blyuss O; Ryan A; Burnell M; Karpinskyj C; Gunu R; Kalsi JK; Dawnay A; Marino IP; Manchanda R; Lu K; Yang WL; Timms JF; Parmar M; Skates SJ; Bast RC; Jacobs IJ; Zaikin A; Menon U
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708856
[TBL] [Abstract][Full Text] [Related]
2. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
Gentry-Maharaj A; Burnell M; Dilley J; Ryan A; Karpinskyj C; Gunu R; Mallett S; Deeks J; Campbell S; Jacobs I; Sundar S; Menon U
Am J Obstet Gynecol; 2020 Jan; 222(1):56.e1-56.e17. PubMed ID: 31351062
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.
Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; Mariño IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U
Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833
[No Abstract] [Full Text] [Related]
4. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
5. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
6. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
7. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
8. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
9. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.
Simmons AR; Clarke CH; Badgwell DB; Lu Z; Sokoll LJ; Lu KH; Zhang Z; Bast RC; Skates SJ
Int J Gynecol Cancer; 2016 Jul; 26(6):1070-7. PubMed ID: 27206285
[TBL] [Abstract][Full Text] [Related]
10. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C
Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
[TBL] [Abstract][Full Text] [Related]
11. Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.
Blyuss O; Gentry-Maharaj A; Fourkala EO; Ryan A; Zaikin A; Menon U; Jacobs I; Timms JF
Biomed Res Int; 2015; 2015():681416. PubMed ID: 26819954
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
[TBL] [Abstract][Full Text] [Related]
14. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
15. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
[TBL] [Abstract][Full Text] [Related]
16. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
18. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
[TBL] [Abstract][Full Text] [Related]
19. The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis.
Micu R; Gaia-Oltean AMI; Budişan L; Braicu C; Irimie A; Berindan-Neagoe I
Rom J Morphol Embryol; 2023; 64(2):159-164. PubMed ID: 37518872
[TBL] [Abstract][Full Text] [Related]
20. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
